TABLE. Facilities planning to retain poliovirus type 2 (PV2),* by World Health Organization (WHO) region, facility type, and PV2 strain†.
| WHO region | No. of countries | No. of facilities planning to retain PV2 materials | Type of PV2 materials retained and no. of facilities |
No. of Salk-IPV production sites | No. of Sabin-IPV production sites§ | No. of diagnostic or research laboratories | ||
|---|---|---|---|---|---|---|---|---|
| WPV2 | Both WPV2/VDPV2 and OPV2/Sabin2 | Only OPV2/Sabin2 | ||||||
| AFR |
2 |
2 |
0 |
2 |
0 |
0 |
0 |
2 |
| AMR |
5 |
27 |
3 |
20 |
4 |
1 |
1 |
25 |
| EMR |
2 |
2 |
0 |
0 |
2 |
0 |
1 |
1 |
| EUR |
14 |
32 |
5 |
24 |
3 |
8 |
2 |
22 |
| SEAR |
2 |
7 |
1 |
0 |
6 |
0 |
6 |
1 |
| WPR |
5 |
16 |
0 |
4 |
12 |
0 |
11 |
5 |
| Total | 30 | 86 | 9 | 50 | 27 | 9 | 21 | 56 |
Abbreviations: AFR = African Region; AMR = Region of the Americas; EMR = Eastern Mediterranean Region; EUR = European Region; IPV = inactivated polio vaccine; OPV = oral poliovirus vaccine; SEAR = South-East Asia Region; VDPV2 = type 2 vaccine–derived poliovirus; WPR = Western Pacific Region; WPV2 = type 2 wild poliovirus.
* Includes WPV2/circulating VDPV2 and OPV2/Sabin2.
† Data as of June 18, 2017.
§ Includes potential future producers in different clinical and preclinical phases of Sabin-IPV development.